Ponderosa pine (Pinus ponderosa), known as western yellow pine (Py), is a dominant tree species in hot, dry environments like the southern interior of British Columbia (BC) and south of the border into Washington state. It is also highly desirable and commercially important as a building material for homes, furniture and more. Py is also highly valued by Indigenous peoples,…
Read More
adMare BioInnovations, Canada’s global life sciences venture, is pleased to announce the launch of Abdera Therapeutics Inc. (Abdera) with founding partner, AbCellera (Nasdaq: ABCL). Abdera is a precision oncology company developing novel next-generation targeted alpha therapies (TATs) for patients with relapsed, refractory and metastatic cancers. The seed financing of Abdera includes a total commitment of CAD $8 million. Abdera will…
Read More
Researchers have found a simple way to eliminate almost all sequencing errors produced by a widely used portable DNA sequencer, potentially enabling scientists working outside the lab to study and track microorganisms like the SARS-CoV-2 virus more efficiently. Using special molecular tags, the team was able to reduce the five-to-15 per cent error rate of Oxford Nanopore Technologies’ MinION device to less than 0.005 per cent…
Read More

The CBR Welcomes Dr. Dana Devine as Director

As of January 1st, 2021, the Centre for Blood Research (CBR) was pleased to welcome Dr. Dana Devine as Director. She succeeds Dr. Ed Conway, the CBR’s previous Director of 11 years. “I’m honoured to accept the position of Director, and look forward to building on the CBR’s successes,” said Dr. Devine. In addition to her long-time work with the…
Read More

Scientists Discover Key Enzyme Responsible for Skin Blistering in the Elderly

The Granzyme B (GzmB) enzyme has been identified as a driver of itchy and sometimes life-threatening pemphigoid diseases (PDs): autoimmune conditions that cause blistering and skin erosion that originate below the skin’s surface. New research led by Vancouver Coastal Health Research Institute (VCHRI) scientist Dr. David Granville has found that a gel containing a specific and potent inhibitor of GzmB…
Read More
After Carl Hansen co-founded AbCellera Biologics Ltd. in 2012, people constantly told him he was building a biotechnology company the wrong way. “The whole sector for years has been focused on this idea that if you wanted to build a valuable company, you have to make your own drugs,” Dr. Hansen told the Globe and Mail Thursday. “It was very…
Read More

Molecular Subtypes of Common Pancreatic Cancers Can Be Predicted from Tumour Characteristics

Gene expression analysis of pancreatic ductal adenocarcinoma (PDAC) tumours enables clinicians to stratify patients into molecular subgroups and select treatments that are best suited to each type; however, molecular subtyping remains cost-prohibitive and is not yet part of routine cancer care. In a new study, researchers used prior gene expression data to show that tumour characteristics can predict molecular subtypes, extending…
Read More
A pilot study has shown that an experimental vaccine for cat allergy can reduce the systemic immune response and symptoms of allergic rhinitis – nasal congestion, sneezing, nasal itching and runny nose – in allergic individuals. The vaccine, called Cat-PAD (Adiga Life Sciences Ltd.), uses peptide immunotherapy to train the immune system not to overreact to the cat allergen Fel d1 –…
Read More

Challenging the Dogma of Innate Lymphoid Cell Development

Have you ever wondered how your body knows to respond to an infection appropriately?  When infected with a virus, why does your body immediately make an anti-viral response, and not an anti-bacterial or an allergic response? Innate lymphoid cells (ILCs) are a relatively new sub-set of immune cells 1. They are on the front lines of your body’s response to infection…
Read More
Bold Therapeutics, a clinical-stage biopharmaceutical company developing BOLD-100, is pleased to announce that it is one of only four companies selected to receive advisory services and research and development funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the company’s development of its antiviral asset, BOLD-100, as a novel antiviral therapy for SARS-CoV-2 (aka COVID-19).…
Read More